Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week we’re breaking down one of the most common and most misleading narratives in biotech right now: the gap between headline patient populations and actual revenue opportunity. Companies love to highlight “millions of patients” and massive unmet need, but that top-line number is only the starting point. We walk through the real funnel, from diagnosis and eligibility to access, reimbursement, and provider capacity, and show how quickly that population shrinks at each step. The result is a much smaller, more constrained market than most investors assume, where logistics, payer behavior, and system throughput matter just as much as clinical efficacy. The core question isn’t how many patients exist, it’s how many actually make it through the system.
📣🎙️ TODAY’S PODCAST:
[ 00:34 ] Concert analogy pitch fails
[ 01:22 ] Biotech funnel problem introduced
[ 02:29 ] Treatment-resistant depression TAM illusion
[ 03:17 ] Revenue opportunity vs societal need
[ 04:17 ] Diagnosis breakdown removes patients
[ 05:22 ] Definition of treatment resistant
[ 06:29 ] Medical eligibility filters reality
[ 07:24 ] Willingness and human psychology barrier
[ 08:57 ] Access and geography constraints
[ 10:52 ] Reimbursement swamp and step therapy
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
